Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
May 2, 2019 Off

Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol

By BusinessWire

Top-line data expected Q3 of 2019 Also reports recent results from clinician survey on radiocontrast agent selection and use SAN…

May 2, 2019 Off

Dermatological Therapeutics Market 2019-2024: Worldwide Growth, Trends, and Forecast Report – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Dermatological Therapeutics Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering.…

May 2, 2019 Off

Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor® in Progesterone Receptor Positive Gynecological Cancers

By BusinessWire

Apristor® (onapristone extended release), a full progesterone receptor antagonist, is being studied in patients with rare gynecological cancers who are…

May 2, 2019 Off

Sunovion Highlights Data from Its Psychiatry Portfolio at the 2019 American Psychiatric Association Annual Meeting

By BusinessWire

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it will present clinical and health economic outcomes data from its…

May 2, 2019 Off

Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings

By BusinessWire

– Recent analyses highlight significant unmet clinical needs and burden of anemia due to chronic kidney disease CAMBRIDGE, Mass. &…

May 2, 2019 Off

Clovis Oncology Enters into Non-Dilutive Clinical Trial Financing with TPG Sixth Street Partners for up to $175 Million

By BusinessWire

Financing to fund quarterly expenses related to the ATHENA first-line maintenance clinical trial in ovarian cancer, beginning in Q2 2019…

May 2, 2019 Off

BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting

By BusinessWire

Treatment with OpRegen® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina Observed in Some Patients…

May 2, 2019 Off

Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates

By BusinessWire

– Selected 150 mg for the dose expansion trial for AB928, the Company’s dual A2a/A2b receptor antagonist, in combination with…

May 2, 2019 Off

Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer

By BusinessWire

HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that William…

May 2, 2019 Off

Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122

By BusinessWire

– Leverages Strata Oncology’s Proprietary Biomarker Technology to Stratify Patients – HAYWARD, Calif. and ANN ARBOR, Mich.–(BUSINESS WIRE)–Arcus Biosciences, Inc.…

Posts pagination

Previous 1 … 3,231 3,232 3,233 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine